ASA 81 MG TABLET (DELAYED-RELEASE)

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

ACETYLSALICYLIC ACID

थमां उपलब्ध:

PHARMASCIENCE INC

ए.टी.सी कोड:

B01AC06

INN (इंटरनेशनल नाम):

ACETYLSALICYLIC ACID

डोज़:

81MG

फार्मास्यूटिकल फॉर्म:

TABLET (DELAYED-RELEASE)

रचना:

ACETYLSALICYLIC ACID 81MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

120

प्रिस्क्रिप्शन प्रकार:

OTC

चिकित्सीय क्षेत्र:

SALICYLATES

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0101169013; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2001-11-30

उत्पाद विशेषताएं

                                PRODUCT MONOGRAPH
ASA 81 MG
Acetylsalicylic
Acid Delayed-release Tablets USP
81 mg
ASA DAILY LOW DOSE
Acetylsalicylic
Acid Tablets USP
81 mg
Platelet aggregation inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Quebec H4P 2T4
DATE OF REVISION:
March 14, 2022
www.pharmascience.com
SUBMISSION CONTROL NUMBER: 261509, 261543
Page 2 of 42
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................4
WARNINGS AND PRECAUTIONS
.............................................................................5
ADVERSE
REACTIONS..............................................................................................7
DRUG INTERACTIONS
..............................................................................................8
DOSAGE AND ADMINISTRATION
.........................................................................
10
OVERDOSAGE
.........................................................................................................
11
ACTION AND CLINICAL
PHARMACOLOGY.........................................................
11
STORAGE AND STABILITY
....................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
................................................................... 13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 13
PART II : SCIENTIFIC INFORMATION
.........................................................................
15
PHARMACEUTICAL INFORMATION
.....................................................................
15
CLINICAL TRIALS
...........................................................................................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 14-03-2022

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें